Cancer Vaccine Triggers Immune System to Recognize Melanoma

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 18 de mayo del 1998

Unlike vaccines that are used to prevent infectious disease, cancer vaccines attempt to stimulate the body's own immune system to recognize cancer cells as foreign and destroy them.

These researchers examined tyrosinase, a normal protein present in melanin (which gives moles their color), and in melanoma cells. Patients were treated with tyrosinase plus QS21, which helps to "energize" the immune system, stimulating the patients immune T-cells to recognize the tyrosinase. They hoped that these same T-cells would recognize the patients' melanoma cells (which also contain the tyrosinase) and destroy them.

In a Phase I trial of 9 patients with Stage III or Stage IV melanoma who also had a certain immune system characteristic (HLA-A2.1 positive), the researchers found that two patients demonstrated a clear and highly significant post-vaccination in crease in immune CD-20+ T-cell frequency against the tyrosinase peptide. No patients experienced any unexpected toxicity, and the trials are ongoing to further augment the immune response and determine the effects in fighting cancer.

[ Original Abstract ]


Breaking news: Supreme Court votes to uphold Affordable Care Act Subsidies
by Christina Bach, MSW, LCSW, OSW-C
June 26, 2015

Related News

Virus-based vaccine found to activate immune systems in some patients with advanced cancers

Aug 3, 2010

Virus-based vaccine found to activate immune systems in some patients with advanced cancers

Inhibition of Immune Pathway May Trigger Melanoma Growth

Apr 3, 2012

Colocalization of immune inhibitory B7-H1 and tumor-infiltrating lymphocytes seen in melanocytes

Early Research Proving Hopeful for Melanoma Vaccine

Apr 6, 2015

Approach could be used against other cancers that typically have a high number of mutated proteins